BRIEF-Halozyme to resume enrollment in Phase 1B trial evaluating PEGPH20 By: Reuters: Company News July 25, 2016 at 09:58 AM EDT * Resumed enrollment, dosing patients in phase 1B trial evaluating investigational new drug, PEGPH20, in combination with KEYTRUDA Read More >> Related Stocks: Halozyme Therapeutic